Senses Disorder TRIZ Cases

Segmented drug delivery system uses hydrolytically degradable polymers to maintain constant therapeutic levels despite variable release kinetics.

A hypoxia-regulated vector produces endostatin in retinal pigment epithelial cells to inhibit pathological neovascularization.

Substituted piperidine derivatives inhibit the ATF4 pathway, addressing the lack of effective inhibitors for neurodegenerative and cancer treatments.

Modifying variable regions of humanized anti-endoglin antibodies reduces immunogenicity while maintaining therapeutic efficacy for cancer and ocular disorders.

Fluoroalkyl substitutions optimize metabolic actions while maintaining anti-inflammatory efficacy for non-steroidal modulators.

Anti-C3b antibodies block C3 cleavage and factor B binding to mitigate tissue injury in septic shock.

Fused heterocyclic compounds inhibit IL-12, IL-23, and IL-27 production to resolve inadequate disease control in autoimmune disorders.

Novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives modulate protein kinase activity to inhibit tumor cell proliferation.

A ciprofloxacin otic suspension maintains liquid state during heat sterilization through precise temperature control and phase transition management.

Selective pyrazole inhibitors target gamma and delta p38 MAPK isoforms to reduce systemic toxicity associated with pan-isoform inhibition.

Targeting endosialin interaction with extracellular matrix proteins suppresses angiogenesis and neovascularization in disease models.

A VEGFR antibody fusion protein fuses vascular endothelial growth factor receptor to the light chain C-terminus for enhanced stability.

Chromatographic separation yields enantiomeric excess above 80% for voltage-gated sodium channel modulation.

Diazeniumdiolate compounds release nitric oxide locally to reduce inflammation without systemic side effects or cancer risks associated with corticosteroids.

Dual PPAR alpha and gamma agonist 1,3-dioxane carboxylic acids lower triglycerides and blood glucose while reducing liver toxicity risks.

A polymer-coated gold nanoparticle-aptamer nanoconstruct scavenges reactive oxygen species and captures TNF-alpha.

Optimized variable regions deliver high potency IL-1β neutralization, resolving cross-reactivity issues in inflammatory disease therapies.

A guanidine compound formula inhibits VAP-1 enzyme activity to treat diabetic nephropathy.

Indolin-2-one derivatives target NMDA glycine sites and inhibit ENT1 to reverse hyperlocomotion, addressing unmet needs in schizophrenia negative symptoms.

Synthetic peptide amides act as selective kappa opioid receptor agonists to deliver targeted analgesia.

Multifunctional antioxidant compounds cross the blood-brain barrier to reduce oxidative stress and metal accumulation in neurological disorders.

Engineered AAV capsids incorporate heterologous peptides into surface-exposed variable regions to enhance cellular uptake and genome integration.

A biodegradable ocular implant delivers therapeutic agents via diffusion and polymer degradation to maintain consistent drug concentrations.

Carboxymethyl-hexanoyl chitosan micelles encapsulate drugs in a colloidal gel, reducing dropping frequency and improving bioavailability.

Engineered multispecific antibodies utilize pH-sensitive binding to transferrin receptor for enhanced brain delivery.

A cell sheet derived from nasal epithelium replaces lost middle ear mucosa, preventing eardrum re-adhesion and restoring gas exchange function.

Clazakizumab blocks interleukin-6 to inhibit donor-specific antibody production, resolving inadequate management of antibody-mediated rejection.

New heterocyclic compounds modulate stearoyl-CoA desaturase to treat metabolic diseases while balancing inhibition efficacy and specificity.

A paint brush-type photodynamic therapy laser targets abnormal retinal vessels using specific wavelengths and photosensitizers.

Membrane attack complex pores enable therapeutic cargo entry into cells, resolving delivery efficiency bottlenecks while reducing toxic agent doses.

Extraction of electrodes reduces catheter diameter, lowering lymphatic pressure and preventing extravasation during cell delivery.

A preservative-free cyclosporine ophthalmic emulsion maintains sterility through specialized packaging and homogenization processes.

Optimized pH and buffering agents stabilize anti-CD105 antibodies, reducing systemic toxicity while maintaining efficacy against angiogenesis-related disorders.

Formula I compounds inhibit autotaxin enzyme activity to reduce disease progression in fibrosis and cancer patients.

Specific polar substituents on the thiazole core enhance water solubility while maintaining receptor binding affinity for pharmaceutical formulations.

Fusion proteins merge VEGFR binding and Fas ligand domains to block angiogenesis while inducing apoptosis in VEGF-secreting cancer cells.

Supercritical carbon dioxide extracts cellular materials from porcine corneas, preserving structural integrity and reducing immune rejection risks.

Selective CB2 receptor agonists deliver anti-inflammatory effects without psychoactive side effects from central nervous system activation.

Oral Tisochrysis lutea composition increases tear production and repairs corneal injuries, addressing dry eye syndrome without frequent reapplication.

Cyclic group structures on heteroaryl moieties enhance inhibitor binding affinity to overcome clinical resistance from F691L and D835Y mutations.

Fused pentacyclic imidazole derivatives modulate human TNFα activity as potent small molecule pharmacological agents.

Engineered zinc finger proteins bind target sites in the PEDF and VEGF genes to modulate gene expression, overcoming single-factor therapy limitations.

Bicyclic TRPV1 antagonists selectively block vanilloid receptors to relieve pain while avoiding side effects from traditional analgesics.

Substituted bicyclic compounds activate S1P1 receptors to modulate lymphocyte trafficking, addressing non-selectivity toward S1P3 receptors.

Segmented extraction with controlled drying resolves the contradiction between high active ingredient concentration and manufacturing simplicity.

Novel imidazoquinoline compounds modulate COX-2 gene expression to reduce inflammatory pain without gastrointestinal toxicity.

A core construct equipped with azide or alkyne groups enables precise click chemistry linkage of therapeutic agents to targeting elements.

Modifying human antibody sequences creates a caninized anti-VEGF agent that effectively treats canine cancer by blocking VEGF-mediated angiogenesis.

Merging ketorolac or diclofenac with atropine suppresses inflammation and chondrogenic proteins, addressing pathologic changes that optical corrections miss.